Focus: HistoSonics is a public biotech company developing the Edison™ System, a non-invasive, autonomous robotic platform using histotripsy technology to treat solid tumors and benign conditions across multiple oncology and urology indications.
Profile data last refreshed 2h ago · AI intelligence enriched 1mo ago
HistoSonics offers early-stage platform optionality and regulatory validation, but limited hiring bandwidth and opaque financials present moderate career risk for those seeking rapid growth or financial transparency.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for HistoSonics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HistoSonics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Why Axsome Stock Has Doubled In Nine Months - forbes.com
Why Axsome Stock Has Doubled In Nine Months forbes.com
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion - BioSpace
HistoSonics Receives Landmark TFDA Approval in Taiwan, Accelerating Global Expansion BioSpace
HistoSonics submits Edison histotripsy tech to FDA for kidney tumors - MassDevice
HistoSonics submits Edison histotripsy tech to FDA for kidney tumors MassDevice
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors - BioSpace
HistoSonics Moves to Advance Additional Histotripsy Applications Announcing FDA Submission for Kidney Tumors BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo